Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agree with all the below and look at how many pharma's have grown this year and we're back at IPO level, it's been a shower unfortunately and I'm really disappointed.
I also don't like the way they have hidden 3 large sellers in nominee accounts on the major shareholders list on the website, not very transparent is it.
Really needs some positive news to improve sentiment
"Regardless of peoples flippant remarks such as (kissei deal is just a myth) etc
It is 100% real it is exceptionally likely and I 100% believe it will be delivered.
My opinion on it is....."
....just an opinion, and I do respect your opinion.
You say that the deal is "100% real and exceptionally likely". On what evidence is that based other than forward looking statements in an RNS? The fact is that there is no deal yet. There is, however, growing evidence to the contrary. Directors leaving and major shareholders dumping their holdings does not suggest transformational deals are imminent. Is anybody really that stupid that they would sell millions of shares if they thought it was about to multi-bag on transformational news, just because they didn't like the people that they used to work with?
Offshore, I'd absolutely love a deal but how is it 'exceptionally likely and I 100% believe it will be delivered'?, I'm just interested in why you're so confident? and what facts you have to back it up? You have to admit we've heard nothing recently to raise confidence in Kissie coming off.
I get that Soup, and thanks for sharing. My response was more in respect of the other replies tbh.
What are your thoughts on final paragraph?
Whimax, my post was just picking up on the irony that not only are Kissei active, they signed a deal with connections to NFX.
Just find it amusing really nothing about whether the deal is comparable.
Like everything, there are 2 ways to look at this (negatively or positively) I guess. Firstly this doesn’t sound like a deal that would in any way be relevant to NFX as payments are TO Kissei and not the other way round, and secondly, you can look on it as Kissei now being back open for business.
The last paragraph, is also interesting, although I’m not 100% sure what it means.
Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines). Kissei receives from Affamed an upfront payment, and will be eligible to receive development milestone payments according to stages of development and royalty payments according to the sales of product.
KDT-3594 is a novel orally administrable non-ergot dopamine agonist, which acts by stimulating dopamine receptors in the basal ganglia, thereby ameliorating the symptoms of Parkinson's Disease caused by insufficient action of dopamine. It is also confirmed as a new therapeutic agent for Parkinson's disease that KDT-3594 reduces the risk of the characteristic side effects of existing ergot and non-ergot dopamine agonists. KDT-3594 is currently under Phase 2 clinical trials in Japan.
Kissei focuses on drug discovery, research and development of new drugs, and aims at international expansion by licensing out strategy. One of the policies of PEGASUS, 5-year medium-term management plan launched in April 2020, is to strengthen earnings base overseas. In collaboration with partner companies, Kissei will contribute to the health of people around the world through developing novel drugs.
The financial effects on Kissei's consolidated business forecasts of the fiscal year ending in March 2021 by this agreement is currently under scrutiny, and will be announced at the time of the announcement of the financial results of the second quarter of the fiscal year ended in March 2021, scheduled on November 5, 2020.
Good research Soup. But depressing, a full time CEO is likely needed to finalise deals, not least because the counter-party will understandably want to know who they are going to be working with. "Coming Soon" doesn't cut it in the real world.
Just more evidence pointing towards a Kissei deal being non-existent. Kissei closing deals elsewhere, 12 months since original rumours, an exodus of directors and heavy selling from major shareholders.
If anything happens with NXP002 then my guess is that it will be with a completely different partner....and the recent heavy selling doesn't suggest that anything along those lines is imminent.
Just by way of comparison, AffaMed hadn't even been founded when there was the Times Kissei 'leak' exactly a year ago.
In one of those small world situations, just found out that EverInsight, who back in June signed an outlicensing deal with Vistagen, have recently merged with AffaMed.
Its one of those small coincidences that AffaMed only two weeks ago signed a licensing agreement with Kissei.
Its almost as if Kissei aren't closed for business as some execs seem to think.